NCT00034385View on ClinicalTrials.gov

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 24, 2002

Primary Completion Date

January 30, 2007

Study Completion Date

October 30, 2009

Conditions
Kidney Trasplant
Interventions
DRUG

Valganciclovir

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00034385 - Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients | Biotech Hunter | Biotech Hunter